scholarly journals Focal Pulsed Field Ablation for Pulmonary Vein Isolation and Linear Atrial Lesions

Author(s):  
Jacob S. Koruth ◽  
Kenji Kuroki ◽  
Iwanari Kawamura ◽  
William C. Stoffregen ◽  
Srinivas R. Dukkipati ◽  
...  
Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S10
Author(s):  
Kuldeep Bharat Shah ◽  
Nishaki Mehta ◽  
Ilana B. Kutinsky ◽  
Mark T. Stewart ◽  
Atul Verma ◽  
...  

2021 ◽  
Author(s):  
Thomas Kueffer ◽  
Samuel Baldinger ◽  
Helge Servatius ◽  
Antonio Madaffari ◽  
Jens Seiler ◽  
...  

Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S407
Author(s):  
Elad Anter ◽  
Hagai Yavin ◽  
Koji Higuchi ◽  
David Biton ◽  
Jakub Sroubek ◽  
...  

Author(s):  
Atul Verma ◽  
Lucas Boersma ◽  
David E. Haines ◽  
Andrea Natale ◽  
Francis E. Marchlinski ◽  
...  

Background: Pulsed field ablation (PFA) is a novel form of ablation using electrical fields to ablate cardiac tissue. There are only limited data assessing the feasibility and safety of this type of ablation in humans. Methods: PULSED AF (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF; https://www.clinicaltrials.gov ; unique identifier: NCT04198701) is a nonrandomized, prospective, multicenter, global, premarket clinical study. The first-in-human pilot phase evaluated the feasibility and efficacy of pulmonary vein isolation using a novel PFA system delivering bipolar, biphasic electrical fields through a circular multielectrode array catheter (PulseSelect; Medtronic, Inc). Thirty-eight patients with paroxysmal or persistent atrial fibrillation were treated in 6 centers in Australia, Canada, the United States, and the Netherlands. The primary outcomes were ability to achieve acute pulmonary vein isolation intraprocedurally and safety at 30 days. Results: Acute electrical isolation was achieved in 100% of pulmonary veins (n=152) in the 38 patients. Skin-to-skin procedure time was 160±91 minutes, left atrial dwell time was 82±35 minutes, and fluoroscopy time was 28±9 minutes. No serious adverse events related to the PFA system occurred in the 30-day follow-up including phrenic nerve injury, esophageal injury, stroke, or death. Conclusions: In this first-in-human clinical study, 100% pulmonary vein isolation was achieved using only PFA with no PFA system–related serious adverse events.


Heart Rhythm ◽  
2021 ◽  
Author(s):  
Iwanari Kawamura ◽  
Petr Neuzil ◽  
Poojita Shrivamurthy ◽  
Jan Petru ◽  
Moritoshi Funasako ◽  
...  

2019 ◽  
Vol 74 (3) ◽  
pp. 315-326 ◽  
Author(s):  
Vivek Y. Reddy ◽  
Petr Neuzil ◽  
Jacob S. Koruth ◽  
Jan Petru ◽  
Moritoshi Funosako ◽  
...  

Author(s):  
Vivek Y. Reddy ◽  
Elad Anter ◽  
Gediminas Rackauskas ◽  
Petr Peichl ◽  
Jacob S. Koruth ◽  
...  

Background: The tissue selectivity of pulsed field ablation (PFA) provides safety advantages over radiofrequency ablation in treating atrial fibrillation. One-shot PFA catheters have been shown capable of performing pulmonary vein isolation, but not flexible lesion sets such as linear lesions. A novel lattice-tip ablation catheter with a compressible 9-mm nitinol tip is able to deliver either focal radiofrequency ablation or PFA lesions, each in 2 to 5 s. Methods: In a 3-center, single-arm, first-in-human trial, the 7.5F lattice catheter was used with a custom mapping system to treat paroxysmal or persistent atrial fibrillation. Toggling between energy sources, point-by-point pulmonary vein encirclement was performed using biphasic PFA posteriorly and either temperature-controlled irrigated radiofrequency ablation or PFA anteriorly (RF/PF or PF/PF, respectively). Linear lesions were created using either PFA or radiofrequency ablation. Results: The 76-patient cohort included 55 paroxysmal and 21 persistent atrial fibrillation patients undergoing either RF/PF (40 patients) or PF/PF (36 patients) ablation. The pulmonary vein isolation therapy duration time (transpiring from first to last lesion) was 22.6±8.3 min/patient, with a mean of 50.1 RF/PF lesions/patient. Linear lesions included 14 mitral (4 RF/2 RF+PF/8 PF), 34 left atrium roof (12 RF/22 PF), and 44 cavotricuspid isthmus (36 RF/8 PF) lines, with therapy duration times of 5.1±3.5, 1.8±2.3, and 2.4±2.1 min/patient, respectively. All lesion sets were acutely successful, using 4.7±3.5 minutes of fluoroscopy. There were no device-related complications, including no strokes. Postprocedure esophagogastroduodenoscopy revealed minor mucosal thermal injury in 2 of 36 RF/PF and 0 of 24 PF/PF patients. Postprocedure brain magnetic resonance imaging revealed diffusion-weighted imaging+/fluid-attenuated inversion recovery- and diffusion-weighted imaging+/fluid-attenuated inversion recovery+ asymptomatic lesions in 5 and 3 of 51 patients, respectively. Conclusions: A novel lattice-tip catheter could safely and rapidly ablate atrial fibrillation using either a combined RF/PF approach (capitalizing on the safety of PFA and the years of experience with radiofrequency energy) or an entirely PF approach. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT04141007 and NCT04194307.


Sign in / Sign up

Export Citation Format

Share Document